Generic Name and Formulations:
Chlorzoxazone 375mg, 750mg+; tabs; +scored.
Various generic manufacturers
Indications for Chlorzoxazone:
As adjunct to rest, physical therapy, and other measures in acute, painful musculoskeletal conditions.
375mg: 1 tab 3–4 times daily; may increase to 2 tabs (750mg) 3–4 times daily if inadequate response. 750mg: ⅓ tab (250mg) 3–4 times daily. Painful musculoskeletal conditions: initially ⅔ tab (500mg) 3–4 times daily; may increase to 1 tab (750mg) 3–4 times daily if inadequate response. May reduce dose based on improvement.
Known drug intolerance.
Monitor for hepatotoxicity; discontinue if hepatic dysfunction or abnormal liver enzymes develop. Known allergies or history of. Discontinue if sensitivity reaction occurs. Pregnancy.
Muscle relaxant (central).
Additive effects with concomitant alcohol, other CNS depressants.
Drowsiness, dizziness, lightheadedness, malaise, overstimulation; rare: skin rash, petechiae, ecchymosis, fatal hepatocellular toxicity.
Formerly known under the brand name Lorzone.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Age of Onset of Bipolar Disorder Linked With Substance Use Disorders
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Short Forms of Parent General Behavior Inventory Reliable at Identifying Youth Mood Symptoms
- Low Testosterone Linked With Social Anxiety in Boys With Klinefelter Syndrome
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Digital Media Engagement Associated With ADHD Symptoms in Adolescents
- Strong Social Networks May Mitigate the Effects of Childhood Adversity
- Unexpected Effect of Substance Use Disorders on Recovery From Bipolar Depression
- Republican Opposition to Obamacare: What's Done, What's to Come
- Early Childhood Out-of-Home Placement Associated With Adverse Outcomes in Adulthood
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Integrating Treatments for Opioid Use Disorder and Infectious Diseases